Abbott Faces Two Separate Cyber Investigations
Abbott Laboratories has confirmed it is investigating two distinct cybersecurity incidents, adding fresh uncertainty for a company that has already been dealing with fallout from extortion-related hacking activity this year. The healthcare and diagnostics giant said it found unauthorized access to internal legacy systems belonging to Exact Sciences, the cancer diagnostics company it owns, within its Cancer Diagnostics business unit. Separately, Abbott is looking into a claim that attackers breached its LabCentral portal and made off with company data.
The two incidents are being treated as unrelated, according to the limited details available so far, though both point to the same underlying reality: large healthcare organizations with sprawling networks of legacy systems, acquired subsidiaries, and external-facing portals present a wide attack surface that is difficult to fully secure.
The Exact Sciences Connection
Abbott's confirmation of unauthorized access to legacy Exact Sciences systems does not exist in a vacuum. Earlier reporting detailed how the extortion group ShinyHunters claimed to have breached Exact Sciences, the Abbott-owned diagnostics company best known for the Cologuard colon cancer screening test. That claim raised concerns about the exposure of sensitive health data tied to cancer screening patients, a category of information that carries significant privacy risk if it ends up in the wrong hands.
Abbott has also previously dealt with a broader wave of attacks tied to the same threat actor. Reporting on how ShinyHunters breached Abbott and NAIC through an Oracle flaw described disruptions connected to cancer drug research operations. Taken together, these incidents suggest Abbott's Cancer Diagnostics and research divisions have been a recurring target, whether through legacy infrastructure, third-party software vulnerabilities, or acquired company systems that were not fully integrated into Abbott's security controls.
LabCentral Extortion Claim Adds a New Front
The second incident under investigation involves a claim that attackers accessed Abbott's LabCentral portal and stole company data, with the perpetrators reportedly using extortion tactics, a pattern common among groups that steal data first and then pressure victims to pay rather than immediately deploying ransomware. Abbott has not detailed the scope of data potentially exposed through LabCentral, and the investigation is ongoing.
What makes this second claim notable is that it appears separate from the Exact Sciences access, meaning Abbott could be facing exposure from two different points of entry rather than a single compromised system. For a company operating across pharmaceuticals, diagnostics, and medical devices, that kind of parallel exposure underscores how difficult it is to draw a single security perimeter around a large, decentralized organization built partly through acquisitions.
What This Means For You
If you are a patient who has used Cologuard, interacted with Exact Sciences, or had lab results processed through Abbott-affiliated systems, these incidents are worth paying attention to even before full details emerge. Health diagnostic data is particularly sensitive because it can reveal medical history, screening results, and personal identifiers that are valuable for identity theft or targeted phishing.
For healthcare workers, lab partners, or vendors who use LabCentral or similar portals, this is a reminder that extortion groups increasingly target the software and access points that connect organizations, rather than just the core corporate network. Legacy systems inherited through mergers and acquisitions, like the Exact Sciences infrastructure Abbott absorbed, often lag behind in patching and monitoring, making them attractive entry points for attackers.
Actionable Takeaways
While Abbott's investigations continue, there are practical steps individuals and organizations connected to the company can take now. Patients and customers should watch for official breach notifications from Abbott or Exact Sciences rather than relying on unverified claims circulating online, and should be cautious of unsolicited emails or calls referencing lab results or account details. Enabling credit monitoring or fraud alerts is a reasonable precaution if you have received care through Abbott-affiliated diagnostics services.
For organizations, this incident is a case study in why legacy systems from acquisitions need active security review rather than being left running on old configurations. Regularly auditing third-party portals like LabCentral, enforcing multi-factor authentication, and segmenting legacy infrastructure from core networks can reduce the chance that one compromised system becomes a foothold for a broader breach.
As more details emerge about the scope of Abbott's two cyber incidents, readers should expect updates on what data, if any, was accessed and what remediation steps the company takes. Until then, the Abbott data breach situation serves as a reminder that even large, well-resourced healthcare companies remain vulnerable when legacy systems and external portals are not treated with the same scrutiny as core infrastructure.
